Prognostic Value of CD166 Expression in Cancers of the Digestive System: A Systematic Review and Meta-Analysis

Abstract

ObjectiveMany studies have reported the prognostic predictive value of CD166 as a cancer stem cell marker in cancers of the digestive system; however, its predictive value remains controversial. Here, we investigate the correlation between CD166 positivity in digestive system cancers and clinicopathological features using meta-analysis.MethodsA comprehensive search in PubMed and ISI Web of Science through March of 2013 was performed. Only articles containing CD166 antigen immunohistochemical staining in cancers of the digestive system were included,including pancreatic cancer, esophageal cancer, gastric cancer and colorectal cancer. Data comparing 3- and 5-year overall survival along with other clinicopathological features were collected.ResultsNine studies with 2553 patients who met the inclusion criteria were included for the analysis. The median rate of CD166 immunohistochemical staining expression was 56% (25.4%–76.3%). In colorectal cancer specifically, the results of a fixed-effects model indicated that CD166-positive expression was an independent marker associated with a smaller tumor burden (T category; RR = 0.93, 95%, CI: 0.88–0.98) but worse spread to nearby lymph nodes (N category; RR = 1.17, 95% CI: 1.05–1.30). The 5-year overall survival rate was showed relationship with cytoplasmic positive staining of CD166 (RR = 1.47 95% 1.21–1.79), but no significant association was found in the pool or any other stratified analysis with 3- or 5- year overall survival rate.ConclusionBased on the published studies, different cellular location of CD166 has distinct prognostic value and cytoplasmic positive expression is associated with worse prognosis outcome. Besides, our results also find CD166 expression indicate advanced T category and N-positive status in colorectal cancer specifically.

Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF‐β signalling

“…Lacking early detection markers and effective therapeutic strategies, GC is usually diagnosed in late stages. Most of GC patients die of recurrence and metastasis, with a poor 5-year survival [2,3]. Dysregulation of normal signalling pathways is part of the transformation process in malignancy.…”

CD44 Expression Is Predictive of Poor Prognosis in Pharyngolaryngeal Cancer: Systematic Review and Meta-Analysis

“…Many researchers have reported that high expression of these markers indicates bad clinical features and poor prognosis (Lee et al 2009;Wang et al 2012;Ni et al 2013). The CSC hypothesis also has been connected to pharyngolaryngeal cancer (Faber et al 2011;Janisiewicz et al 2012), and CD44 was one of the most reported CSC markers.…”

Cloning and Expression of C2 and V Domains of ALCAM Protein in E. coli BL21 (DE3)

“…ALCAM is considered as a stem cell marker in colorectal [28][29][30][31][32] prostate [33,34] and glioblastoma cancer [35]. Cancer stem cells are a small subset of cancer cells that have considerable ability in selfrenewal and differentiation [36][37][38][39][40][41][42][43][44][45][46][47][48].…”